Karyopharm: Prelim Revenue, 2022 Objectives

 - Unaudited Net Product Revenues of Approximately $29.7 Million for Fourth Quarter 2021 and Approximately $98.3 Million for the Full Year 2021-

- Company on Track to Announce Top-Line Phase 3 Data from SIENDO Study Evaluating XPOVIO® (selinexor) in Patients with Endometrial Cancer in First Quarter 2022 -

Listen to the Webcast

These achievements and updates will be discussed during a webcast presentation at the 40th Annual J.P. Morgan Healthcare Conference to be held on Tuesday, January 11, 2022, at 3:45 p.m. ET, followed by a question-and-answer breakout session at 4:05 p.m. ET. A live webcast of the presentation and breakout session, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived replay will be available for 30 days following the event. The presentation slides will also be available on the Company's website following the event.

https://finance.yahoo.com/news/karyopharm-announces-preliminary-unaudited-fourth-120000971.html